Korean Circ J.  2012 Mar;42(3):151-153. 10.4070/kcj.2012.42.3.151.

The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease

• Seo HS

• KMID: 2225028
• DOI: http://doi.org/10.4070/kcj.2012.42.3.151

Abstract

No abstract available.

MeSH Terms

C-Reactive Protein
Cardiovascular Diseases
C-Reactive Protein

Reference

1. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003. 96:793–807.

2. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005. 288:H2031–H2041.

3. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005. 135:562–566.

4. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004. 350:1387–1397.

5. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001. 344:1959–1965.

6. Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Arterioscler Thromb Vasc Biol. 2006. 26:2745–2751.

7. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008. 359:1897–1908.

8. Devaraj S, Jiala I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol. 2011. 31:1397–1402.

9. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006. 440:1217–1221.

10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008. 359:2195–2207.

11. Jonathan Emberson, Derrick Bennett, Emma Link, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011. 377:469–476.

12. Ahmed K, Jeong MH, Chakraborty R, et al. Prognostic impact of baseline high-sensitivity C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention based on body mass index. Korean Circ J. 2012. 42:164–172.

13. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010. 122:2748–2764.